dhodh

DHODH-IN-1 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 25 nM. DHODH-IN-1 is an inhibitor of the pyrimidine biosynthetic pathway.

DHODH-IN-12 is a leflunomide derivative and a weak dihydrorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.

DHODH-IN-13 is an inhibitor of DHODH with IC50 of 4.3 μM for rat liver. DHODH-IN-13 can be used in studies about rheumatoid arthritis.

DHODH-IN-14 is an analog of hydroxyfuran pyrimidine A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor IC50 0.49 μM mouse liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis.

DHODH-IN-15 is the hydroxyfuran analogue of A771726. DHODH-IN-15 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 11 μM for rat liver DHODH. DHODH-IN-15 can be used for rheumatoid arthritis.

DHODH-IN-4 is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor. The IC50 values of PfDHODH and HsDHODH are 4 μM and 0.18 μM, respectively. DHODH-IN-4 has antimalarial activity.

DHODH-IN-8 has antimalarial activity. DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC50 of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively.

DHODH-IN-17 is a human DHODH inhibitor with an IC50 of 0.40 μM. DHODH-IN-17 is a 2- anilino nicotinic acid that can be used in the study of acute myeloid leukemia (AML).

DHODH-IN-11 is a leflunomide derivative and weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.03.

DHODH-IN-16 is an effective inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 0.396 nM for human).

DHODH-IN-3 is an effective inhibitor of human dihydroorotate dehydrogenase (HsDHODH) with IC50 value of 261 nM. DHODH-IN-3 binds to the ubiquinone binding cavity in DHODH with a Kiapp of 32 nM. DHODH-IN-3 has the potential to treat malaria.

DHODH-IN-18 is a human DHODH inhibitor with an IC50 value of 0.2 nM.

hDHODH-IN-3 is an inhibitor of human dihydroorotate dehydrogenase with a pMIC50 value of 8.6. hDHODH-IN-3 can inhibit measles virus replication.

hDHODH-IN-7 (DHODH-IN-9) is a nitrogen-containing analog and is a human dihydrorotatory dehydrogenase inhibitor. hDHODH-IN-7 and pMIC50 of 7.4 have antiviral effects.

hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor exhibiting anti-inflammatory properties.

PfDHODH-IN-2 is a dihydrothiophenone derivative, is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH, IC50 : 1.11 μM) inhibitor . It is used an antimalarial agent and can be used for the research of malaria

hDHODH-IN-4 (DHODH-IN-5) is a potent inhibitor of human dihydrogen dehydrogenase (DHODH). For human recombinant DHODH, its pIC50 is 7.8. hDHODH-IN-4 inhibits measles virus replication with a pMIC50 of 8.8.

hDHODH-IN-5 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH, IC50 = 0.91 μM).

DSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.

Olorofim(F-901318)is a novel selective antifungal compound targeting pyrimidine biosynthesis in mycobacteria, with inhibitory effect on Aspergillus fumigatus DHODH (IC50: 44 nM), but little inhibitory effect on human DHODH (>100 uM).Olorofim has good efficacy against a variety of pathogenic filamentous and dimorphic fungi, such as Penicillium spp, P. dermatitidis spp and Fusarium spp.

Atovaquone (Atavaquone) is a hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.

ML390 exerts its potent differentiation effect on multiple leukemia models.

CHIKV-IN-2, a chemical compound, exhibits potent inhibitory activity against the enzyme Dihydroorotate Dehydrogenase (DHODH), crucial for pyrimidine synthesis affecting various viruses' replication. It serves as an effective Chikungunya virus (CHIKV) inhibitor, demonstrating significant cellular antiviral activity (EC90=270 nM) and enhanced liver microsomal stability[1].

Farudodstat (ASLAN003) is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity, showing potential as a first-in-class candidate in AML [Acute Myeloid Leukemia].